<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996436</url>
  </required_header>
  <id_info>
    <org_study_id>IVT_201310 (HSC-MS-13-0586)</org_study_id>
    <nct_id>NCT01996436</nct_id>
  </id_info>
  <brief_title>The Intra-arterial Vasospasm Trial</brief_title>
  <acronym>iVAST</acronym>
  <official_title>The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lenox Hill Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the optimal intra-arterial drug treatment
      regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal
      subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome at 90 days
      post discharge following optimal intra-arterial drug treatment for cerebral vasospasm.

      We hypothesize that Intra-arterial (IA) infusion of a combination of multiple vasodilators is
      more efficacious than single agent treatment cerebral vasospasm therapy.

      All procedures done as a part of this study are standard hospital care procedures done to
      treat cerebral vasospasm and all drugs to be used are FDA approved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine the optimal intra-arterial drug treatment
      regimen for arterial lumen restoration post cerebral vasospasm following aneurysmal
      subarachnoid hemorrhage.

      The secondary objective is to evaluate clinical outcome at 90 days post discharge following
      optimal intra-arterial drug treatment for cerebral vasospasm.

      This study is a prospective multicenter randomized trial. The primary outcome measure is the
      Post infusion improvement ratio (PIIR) assessed 10 minutes after completion of the
      intra-arterial infusion. PIIR is a measure of arterial lumen diameter pre and post
      intra-arterial drug infusion in the presenting vasospasmic blood vessel.

      Modified Rankin score (mRS) at 3 months post hospital discharge will be recorded as a
      secondary outcome to assess clinical outcome.

      The interventions in this study are a part of routine standard of care (SOC) procedures for
      cerebral vasospasm treatment. Following surgical or endovascular intervention for aneurysmal
      Subarachnoid Hemorrhage (aSAH) if patients develop cerebral vasospasm refractory to maximal
      medical management, endovascular treatment by intra-arterial drug infusion of single drug
      agent or cocktail drug agents will be initiated.

      Study participants will be randomly assigned to one of the three treatment groups where one
      single drug agent or cocktail drug agents will be intra-arterially administered. Pre &amp; post
      infusion vasospasmic vessel diameters will be compared. The change in diameter will be
      quantified based on the mean percentage change. Three months post hospital discharge, study
      participants will be followed up in clinic to evaluate clinical outcome.

      The study will require 330 patients in total. The patient population will be hospitalized
      patients presenting with cerebral vasospasm post aneurysmal subarachnoid hemorrhage.

      Subjects will be stratified by randomization into 3 treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post infusion improvement ratio(PIIR)</measure>
    <time_frame>pre pharmacological angioplasty blood vessel diameter - 0 min, post pharmacological angioplasty blood vessel diameter- 10 min after infusion</time_frame>
    <description>Post infusion improvement ratio(PIIR) = (B - A) / A
A = pre-infusion blood vessel diameter B = post infusion blood vessel diameter
PIIR across all four treatment arms will be compared and tested for statistical significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To grade clinical outcome using Modified Rankin score</measure>
    <time_frame>3 months post discharge from hospital</time_frame>
    <description>Clinical outcome at 3 months post discharge from hospital after treatment will be evaluated using Modified Rankin score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intra-cranial pressure</measure>
    <time_frame>1 day prior to procedure &amp; 1 day after the procedure</time_frame>
    <description>Intra-cranial pressure will be measured 1 day prior to vasospasm treatment and 1 day after vasospasm treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicardipine + Verapamil + Nitroglycerin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Nicardipine</arm_group_label>
    <other_name>Cardene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine + Verapamil + Nitroglycerin</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Nicardipine + Verapamil + Nitroglycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient, age 18-80 years old, with ruptured aneurysm(s) who experience cerebral
             vasospasm post operatively within 3-21 days.

        Exclusion Criteria:

          -  Inability to obtain consent from patient or patients kin

          -  Pregnant women

          -  less than 18 years of age of more than 80 years of age

          -  Hunt Hess Grade 5 SAH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng R Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ketan R Bulsara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng R Chen, MD</last_name>
    <phone>713-704-7100</phone>
    <email>Peng.R.Chen@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aditya A Sanzgiri, MBBS, MPH</last_name>
    <phone>713-704-7100</phone>
    <phone_ext>7263</phone_ext>
    <email>Aditya.A.Sanzgiri@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Petersen, MD</last_name>
      <email>nils.petersen@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Nils Petersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Alaraj, MD</last_name>
      <phone>312-996-4842</phone>
      <email>alaraj@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Ali Alaraj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aditya Pandey, MD</last_name>
      <phone>734-615-4486</phone>
      <email>adityap@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Ledoux, MD</last_name>
      <phone>516-562-3590</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lenox Hill</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Ledoux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Wolfe, MD</last_name>
      <phone>336-716-3842</phone>
      <email>sqwolfe@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Jenkins</last_name>
      <phone>336.716.3842</phone>
      <email>mailto:wejenkin@wakehealth.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Schirmer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tejal Raichura</last_name>
      <phone>570.214.6084</phone>
      <email>taraichura@geisinger.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal M Jabbour, MD</last_name>
      <phone>215-955-7000</phone>
      <email>Pascal.Jabbour@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Pascal M Jabbour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kadir Erkmen, MD</last_name>
      <phone>617-697-4722</phone>
      <email>Kadir.Erkmen@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Hatala</last_name>
      <email>Kathleen.Hatala@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sheth, MD</last_name>
      <email>Sunil.A.Sheth@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aditya A Sanzgiri, MBBS MPH</last_name>
      <phone>713-704-7263</phone>
      <email>Aditya.A.Sanzgiri@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sunil Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci. 1994 Jan;1(1):19-26.</citation>
    <PMID>18638721</PMID>
  </reference>
  <reference>
    <citation>Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003 May;98(5):978-84. Review. Erratum in: J Neurosurg. 2003 Dec;99(6):1119.</citation>
    <PMID>12744357</PMID>
  </reference>
  <reference>
    <citation>Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke. 1988 Oct;19(10):1300-5.</citation>
    <PMID>3176090</PMID>
  </reference>
  <reference>
    <citation>Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985 Jul-Aug;16(4):562-72. Review.</citation>
    <PMID>3895589</PMID>
  </reference>
  <reference>
    <citation>Keuskamp J, Murali R, Chao KH. High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008 Mar;108(3):458-63. doi: 10.3171/JNS/2008/108/3/0458.</citation>
    <PMID>18312091</PMID>
  </reference>
  <reference>
    <citation>Linfante I, Delgado-Mederos R, Andreone V, Gounis M, Hendricks L, Wakhloo AK. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery. 2008 Dec;63(6):1080-6; discussion 1086-7. doi: 10.1227/01.NEU.0000327698.66596.35.</citation>
    <PMID>19057319</PMID>
  </reference>
  <reference>
    <citation>Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, Rordorf GA. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004 May;25(5):819-26.</citation>
    <PMID>15140728</PMID>
  </reference>
  <reference>
    <citation>Pierot L, Aggour M, Moret J. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care. 2010 Apr;16(2):110-6. doi: 10.1097/MCC.0b013e3283372ef2. Review.</citation>
    <PMID>20098322</PMID>
  </reference>
  <reference>
    <citation>Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008 Mar;39(3):893-8. doi: 10.1161/STROKEAHA.107.492447. Epub 2008 Jan 31.</citation>
    <PMID>18239182</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Peng Roc Chen</investigator_full_name>
    <investigator_title>Associate Professor - Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>cerebral vasospasm</keyword>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>intra arterial drug treatment for cerebral vasospasm</keyword>
  <keyword>nicardipine milrinone nitroglycerin verapamil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

